Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Nivolumab plus chemo offers prolonged survival in resectable NSCLC

Nivolumab plus chemo offers prolonged survival in resectable NSCLC

14 Jun 2024 bởiStephen Padilla

Patients with resectable nonsmall cell lung cancer (NSCLC) enjoy sustained survival from neoadjuvant nivolumab when added to chemotherapy compared with chemotherapy alone, as seen in the 4-year analysis from the phase III CheckMate 816 study.

14 Jun 2024